Yashica Pharmaceuticals
Yashica Pharmaceuticals
Yashica Pharmaceuticals

Yashica Pharmaceuticals


Yashica PharmaceuticalsYashica Pharmaceuticals

Home » Finished Formulation » Thioridazine Hydrochloride Tablets

Thioridazine Hydrochloride Tablets

Well-formulated and precise array of thioridazine tablets is offered to our clients. It is a phenothiazine group antipsychotic drug that is used for the treatment of psychosis and schizophrenia. Thioridazine Hcl/ Hydrochloride tab is delivered with 100 mg strength capacity.

  • Thioridazine hydrochloride USP 100 mg,
  • N05AC02
Therapeutic category:
  • Antipsychotic drug belonging to the phenothiazine drug group
  • Effects apparently caused by dopamine receptor blocking in CNS.
  • Absorption: more than 95% bound to plasma proteins.
  • Metabolism: metabolized by CYP2D6, main active metabolite is mesoridazine.
  • Elimination: plasma half-life is approximately 4 to 10 h.
Indications and usage:
  • Management of schizophrenia
Dosage & administration:
  • As directed by the physician
  • Adults: The usual starting dose for adult schizophrenic patients is 50 mg to 100 mg three times a day, with a gradual increase to a maximum of 800 mg daily if necessary. Once effective control of symptoms has been achieved, the dosage may be reduced gradually to determine the minimum maintenance dose. The total daily dosage ranges from 200 mg to 800 mg, divided into two to four doses.
  • Pediatric Patients: For pediatric patients with schizophrenia who are unresponsive to other agents, the recommended initial dose is 0.5 mg/kg/day given in divided doses. Dosage may be increased gradually until optimum therapeutic effect is obtained or the maximum dose of 3 mg/kg/day has been reached.
  • Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. Thioridazine is contraindicated in severe CNS depression or comatose states from any cause including drug induced CNS depression. It should also be noted that hypertensive or hypotensive heart disease of extreme degree is a contraindication of phenothiazine administration. Co-administration of drugs that inhibit P450 2D6 with thioridazine and the use of thioridazine in patients known to have reduced activity of P450 2D6 are contraindicated.
Warning & precautions:
  • Thioridazine hydrochloride is not approved for the treatment of elderly patients with dementia- related psychosis due to increased risk of mortality.
  • Thioridazine should only be used in patients who have not shown improvement with or are unable to take other medicines. In schizophrenic patients with epilepsy, anticonvulsant medication should be maintained during treatment with thioridazine. pigmentary retinopathy due to taking larger than recommended doses, characterized by diminution of visual acuity, brownish coloring of vision and impairment of night vision, may occur. The possibility of this complication may be reduced by remaining within the recommended limits of dosage. Caution is recommended where patients are participating in activities requiring complete mental alertness for example driving or operating machineries. The drug elevates prolactin level of the patient which persists during chronic administration.
Drug interactions:
  • Reduced cytochrome P450 2D6 isozyme activity, drugs which inhibit this isozyme (fluoxetine & paroxetine) and certain other drugs (such as fluvoxamine, propranolol & pindolol) appear to appreciably inhibit the metabolism of thioridazine. The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as torsades de pointes type arrhythmias. Such an increased risk may result also from the additive effect of co- administering thioridazine with other agents that prolong the QTc interval. Therefore, thioridazine is contraindicated with these drugs as well as in patients who are known to have a genetic defect leading to reduced levels of activity of P450 2D6. Drugs that reduce the clearance of thioridazine through other mechanisms are fluvoxamine, propranolol, pindolol.
Adverse effects:
  • Common adverse effects are agitation, constipation, diarrhea, dizziness, drowsiness, dry mouth, enlarged pupils, jitteriness, nausea, stuffy nose, vomiting, rash, hives, itching, difficulty breathing, tightness in the chest or throat, swelling of the mouth, face, lips, or tongue, unusual hoarseness, wheezing, chest pain, confusion, decreased coordination, drooling, fainting, fast, slow or irregular heartbeat, mask-like face, muscle spasms of the face, neck or back, muscle weakness, new or worsening mental or mood problems, numbness of an arm or leg, prolonged or painful erection, restlessness, seizures, severe or persistent constipation, severe or persistent headache, shuffling walk, stiff or rigid muscles, sudden shortness of breath or vomiting, swelling of the hands, ankles or feet, fever, chills, persistent sore throat, yellowing of the skin or eyes, dark urine, pale stools, severe or persistent nausea, stomach pain or loss of appetite), tremor, urinating trouble, twisting or twitching movements, uncontrolled muscle movements, unusual bruising or bleeding, unusual eye movements or inability to move eyes, unusual or excessive sweating, unusually pale skin, blurred vision.
  • Store under controlled temperature below 25℃. Protect from light
  • 500 Tablets in a plastic jar

Yes! I am Interested

Yashica Pharmaceuticals

Our Product Range :     Active Pharmaceuticals Ingredients |Drug Intermediates | Finished Formulation

Home|About Us|Our Product Range|Media Gallery|Contact Us|Enquiry

Member INDIAMART© Yashica Pharmaceuticals Private Limited. All Rights Reserved (Terms of Use)
Developed and Managed by IndiaMART InterMESH Limited

Looking for Product Name ?


Send SMS Enquiry

*Please Enter Requirment

*Please Enter valid Mobile Number

*Please Enter Proper Name